Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 – Preliminary reportChristopher W. Seymour, Anthony Gordon, Paul Mouncey et al.|medRxiv|2021Cited by 137
Tocilizumab, sarilumab and anakinra in critically ill patients with COVID-19: a randomised, controlled, open-label, adaptive platform trialLennie Derde, Ville Pettilä, Anthony Gordon et al.|Thorax|2025Cited by 12
Continuation of therapeutic dose heparin for critically ill patients with COVID-19Charlotte Bradbury, Edward Litton, Patrick R. Lawler et al.|Intensive Care Medicine|2023Cited by 6
60 Assessing hyaluronidase-facilitated subcutaneous immunoglobulin 20% (fSCIG 20%) pharmacokinetics, safety and tolerability in primary immunodeficiency diseases: phase 2/3 study designRichard LWasserman, Zhaoyang Li, Liang-Hui Chu et al.|Clinical Immunology|2024Cited by 0